GRIMES & Co WEALTH MANAGEMENT LLC Increases Stock Holdings in Boston Scientific Corporation $BSX

GRIMES & Co WEALTH MANAGEMENT LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 188.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,409 shares of the medical equipment provider’s stock after buying an additional 15,947 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Boston Scientific were worth $2,383,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in BSX. Bogart Wealth LLC grew its holdings in Boston Scientific by 2.4% in the 3rd quarter. Bogart Wealth LLC now owns 67,562 shares of the medical equipment provider’s stock valued at $6,596,000 after buying an additional 1,571 shares during the period. PKO Investment Management Joint Stock Co grew its holdings in Boston Scientific by 69.2% in the third quarter. PKO Investment Management Joint Stock Co now owns 22,000 shares of the medical equipment provider’s stock valued at $2,148,000 after purchasing an additional 9,000 shares during the period. RWC Asset Management LLP increased its position in Boston Scientific by 38.5% during the third quarter. RWC Asset Management LLP now owns 3,848 shares of the medical equipment provider’s stock worth $376,000 after purchasing an additional 1,069 shares during the last quarter. Schmidt P J Investment Management Inc. raised its stake in Boston Scientific by 6.4% during the third quarter. Schmidt P J Investment Management Inc. now owns 15,326 shares of the medical equipment provider’s stock worth $1,496,000 after purchasing an additional 918 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in shares of Boston Scientific by 11.1% in the 3rd quarter. Nordea Investment Management AB now owns 143,313 shares of the medical equipment provider’s stock valued at $13,984,000 after purchasing an additional 14,262 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.8%

NYSE BSX opened at $94.02 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The business has a 50 day moving average price of $97.43 and a two-hundred day moving average price of $100.58. The stock has a market cap of $139.37 billion, a PE ratio of 50.28, a P/E/G ratio of 1.69 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BSX shares. Robert W. Baird upped their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Truist Financial cut their price objective on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. The Goldman Sachs Group reiterated a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday. Finally, Wells Fargo & Company increased their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $125.21.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.